talabostat: Clinical Trials

5 trials of talabostat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5
Phase 11Completed 1

Follow talabostat: new trials by email Literature Review of talabostat trials Research Report on talabostat

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Talabostat, Pembrolizumab - Prostate Cancer, Neuroendocrine Tumors
Phase 1 / Phase 2CompletedBioXcel Therapeutics Inc972019-06-102026-11-10
Study of Talabostat and Cisplatin in Advanced Melanoma
talabostat (PT-100) tablets, cisplatin - Melanoma, Skin Cancer
Phase 2CompletedPoint Therapeutics2007-06-08
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Talabostat mesylate (PT-100) tablets, Rituximab - Chronic Lymphocytic Leukemia
Phase 2CompletedPoint Therapeutics2015-03-25
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
talabostat (PT-100) tablets, Docetaxel - Lung Cancer
Phase 2CompletedPoint Therapeutics2007-06-08
Study of Talabostat in Advanced Melanoma
talabostat (PT-100) tablets - Melanoma, Skin Cancer
Phase 2CompletedPoint Therapeutics2007-06-08

Conditions studied

Melanoma (2)  ·  Skin Neoplasms (2)  ·  Carcinoma, Small Cell (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lung Neoplasms (1)  ·  Neuroendocrine Tumors (1)  ·  Prostatic Neoplasms (1)

Sponsors

Point Therapeutics (4)  ·  BioXcel Therapeutics Inc (1)

Countries

United States (5)  ·  United Kingdom (1)

Results publications

PMID 42114950